Behavioral abnormalities in female mice following administration of aluminum adjuvants and the human papillomavirus (HPV) vaccine Gardasil (Q34677865)

3 August 2017

title

Behavioral abnormalities in female mice following administration of aluminum adjuvants and the human papillomavirus (HPV) vaccine Gardasil (English)

1 reference

3 August 2017

0 references

1 reference

human papilloma virus

1 reference

human papillomavirus

29 September 2024

Yehuda Shoenfeld

1 reference

3 August 2017

Lucija Tomljenovic

1 reference

3 August 2017

Christopher A Shaw

1 reference

3 August 2017

Maria-Teresa Arango

1 reference

3 August 2017

Miri Blank

1 reference

3 August 2017

Joab Chapman

1 reference

3 August 2017

Rotem Inbar

1 reference

3 August 2017

Ronen Weiss

1 reference

3 August 2017

Yael Deri

1 reference

3 August 2017

publication date

16 July 2016

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

page(s)

136-149

1 reference

A meta-analysis of intradermal versus intramuscular influenza vaccines: immunogenicity and adverse events

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Postural tachycardia syndrome following human papillomavirus vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Late onset of Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Aluminium-based adjuvants should not be used as placebos in clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Autoimmune/autoinflammatory syndrome induced by adjuvants (ASIA syndrome) in commercial sheep.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Long-term persistence of vaccine-derived aluminum hydroxide is associated with chronic cognitive dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Biopersistence and brain translocation of aluminum adjuvants of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Clinical features in patients with long-lasting macrophagic myofasciitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Towards an understanding of the adjuvant action of aluminium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Aluminum hydroxide injections lead to motor deficits and motor neuron degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Glia activation induced by peripheral administration of aluminum oxide nanoparticles in rat brains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Immunotoxicity of aluminum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Manufactured aluminum oxide nanoparticles decrease expression of tight junction proteins in brain vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Infections, vaccines and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Human papillomavirus (HPV) vaccine policy and evidence-based medicine: are they at odds?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

The mouse forced swim test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Hyperactivity in a mouse model of the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Vaccines, adjuvants and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Are there negative CNS impacts of aluminum adjuvants used in vaccines and immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Aluminium adjuvants and adverse events in sub-cutaneous allergy immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Long-term follow-up of cognitive dysfunction in patients with aluminum hydroxide-induced macrophagic myofasciitis (MMF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Immunization with hepatitis B vaccine accelerates SLE-like disease in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

The cellular toxicity of aluminium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Aluminum in the central nervous system (CNS): toxicity in humans and animals, vaccine adjuvants, and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Addressing parents' concerns: do vaccines contain harmful preservatives, adjuvants, additives, or residuals?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Slow CCL2-dependent translocation of biopersistent particles from muscle to brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

A longitudinal study of rats chronically exposed to aluminum at human dietary levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Aluminum chloride- and norepinephrine-induced immunotoxicity on splenic lymphocytes by activating β2-AR/cAMP/PKA/NF-κB signal pathway in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Association of acute cerebellar ataxia and human papilloma virus vaccination: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Are the currently existing anti-human papillomavirus vaccines appropriate for the developing world?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Acute disseminated encephalomyelitis following vaccination against human papilloma virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

CNS demyelination and quadrivalent HPV vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Demyelinating disease and polyvalent human papilloma virus vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Opsoclonus Myoclonus after human papilloma virus vaccine in a pediatric patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Neuromyelitis optica following human papillomavirus vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

A 16-year-old girl with bilateral visual loss and left hemiparesis following an immunization against human papilloma virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

impact of aluminum exposure on the immune system: a mini review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Postural Orthostatic Tachycardia With Chronic Fatigue After HPV Vaccination as Part of the "Autoimmune/Auto-inflammatory Syndrome Induced by Adjuvants": Case Report and Literature Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Autoimmune neuromyotonia following human papilloma virus vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Adolescent Premature Ovarian Insufficiency Following Human Papillomavirus Vaccination: A Case Series Seen in General Practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Systemic lupus erythematosus following HPV immunization or infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Human papillomavirus vaccine and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8826-6

Brachial plexus neuritis following HPV vaccination

21 January 2018

1 reference

12 December 2020

Quantifying the possible cross-reactivity risk of an HPV16 vaccine.

1 reference

12 December 2020

Demyelinating disease and vaccination of the human papillomavirus

1 reference

12 December 2020

No autoimmune safety signal after vaccination with quadrivalent HPV vaccine Gardasil?

1 reference

12 December 2020

Vaccine components and constituents: responding to consumer concerns.

1 reference

12 December 2020

Atypical presentation of macrophagic myofasciitis 10 years post vaccination

1 reference

12 December 2020

Potential cross-reactivity between HPV16 L1 protein and sudden death-associated antigens

1 reference

12 December 2020

Vasculitis following HPV immunization

1 reference

12 December 2020

Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines

1 reference

12 December 2020

Complex regional pain syndrome following immunisation

1 reference

12 December 2020

Induction of decreased fecundity by tetanus toxoid hyper-immunization in C57BL/6 mice depends on the applied adjuvant

1 reference

12 December 2020

Vaccination as an additional player in the mosaic of autoimmunity

1 reference

12 December 2020

Autoimmune hepatitis type 2 following anti-papillomavirus vaccination in a 11-year-old girl

1 reference

12 December 2020

Fibromyalgia-like illness in 2 girls after human papillomavirus vaccination

1 reference

12 December 2020

Autoimmune/auto-inflammatory syndrome induced by adjuvants (ASIA) after quadrivalent human papillomavirus vaccination in Colombians: a call for personalised medicine

1 reference

12 December 2020

Inside clinical trials: testing medical products in people

1 reference

12 December 2020

[Acute disseminated encephalomyelitis with tumefactive lesions after vaccination against human papillomavirus]

1 reference

12 December 2020

Pancreatitis following human papillomavirus vaccination

1 reference

12 December 2020

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial

1 reference

12 December 2020

Immune thrombocytopenic purpura following human papillomavirus vaccination

1 reference

12 December 2020

Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia

1 reference

12 December 2020

10.1007/S12026-016-8826-6

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

1032479327

0 references

1 reference